{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:41:11Z","timestamp":1789684871619,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["No.2018zzts262"],"award-info":[{"award-number":["No.2018zzts262"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201806370101"],"award-info":[{"award-number":["201806370101"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201806375066"],"award-info":[{"award-number":["201806375066"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2018JJ3762"],"award-info":[{"award-number":["2018JJ3762"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lymphocyte cytosolic protein 2 (<jats:italic>LCP2<\/jats:italic>) is one of the SLP-76 family of adapters, which are critical intermediates in signal cascades downstream of several receptors. <jats:italic>LCP2<\/jats:italic> regulates immunoreceptor signaling (such as T-cell receptors) and is also required for integrin signaling in neutrophils and platelets. However, the role of <jats:italic>LCP2<\/jats:italic> in the tumor microenvironment is still unknown. In this study, we found a significant increase of mRNA and protein expression of <jats:italic>LCP2<\/jats:italic> in metastatic skin cutaneous melanoma compared to normal skin. The upregulation of <jats:italic>LCP2<\/jats:italic> was associated with good overall survival of patients with metastatic skin cutaneous melanoma, who received pharmacotherapy and radiation. GSEA signaling pathways analysis showed that <jats:italic>LCP2<\/jats:italic> was involved in multiple pathways of immune response and correlation analysis revealed <jats:italic>LCP2<\/jats:italic> was positively correlated with molecules in TCR signaling and 11 immune checkpoints, while <jats:italic>LCP2<\/jats:italic> negatively correlated with 2 immune checkpoints in the metastatic skin cutaneous melanoma. According to the different expressions of <jats:italic>LCP2<\/jats:italic>, high <jats:italic>LCP2<\/jats:italic> expression was positively correlated with more tumor-infiltrating CD8<jats:sup>+<\/jats:sup> T cells. Furthermore, Kaplan\u2013Meier plot indicated that <jats:italic>LCP2<\/jats:italic> acted as a prognostic biomarker for progression-free survival of patients with metastatic skin cutaneous melanoma receiving anti-PD1 immunotherapy. In conclusion, our results integrated both the expression and function of <jats:italic>LCP2<\/jats:italic> in melanoma using multiple tools, shedding light on the potential role of <jats:italic>LCP2<\/jats:italic> in melanoma, and suggesting <jats:italic>LCP2<\/jats:italic> serves as a prognostic biomarker and therapeutic target in anti-tumor immunity.<\/jats:p>","DOI":"10.1038\/s41598-021-88676-9","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T10:04:55Z","timestamp":1619604295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["A novel prognostic biomarker LCP2 correlates with metastatic melanoma-infiltrating CD8+ T cells"],"prefix":"10.1038","volume":"11","author":[{"given":"Zijun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mou","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"88676_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1162-y","author":"E Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz, E. et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature https:\/\/doi.org\/10.1038\/s41586-019-1162-y (2019).","journal-title":"Nature"},{"key":"88676_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00262-017-2072-1","volume":"67","author":"T Balatoni","year":"2018","unstructured":"Balatoni, T. et al. Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy. Cancer Immunol. Immunother. 67, 141\u2013151. https:\/\/doi.org\/10.1007\/s00262-017-2072-1 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"88676_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s40425-019-0828-1","volume":"7","author":"NB Wagner","year":"2019","unstructured":"Wagner, N. B. et al. Tumor microenvironment-derived S100A8\/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J. Immunother. Cancer 7, 343. https:\/\/doi.org\/10.1186\/s40425-019-0828-1 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"88676_CR4","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1002\/cam4.2583","volume":"8","author":"L Peng","year":"2019","unstructured":"Peng, L., Chen, Z., Chen, Y., Wang, X. & Tang, N. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. Cancer Med. 8, 7161\u20137173. https:\/\/doi.org\/10.1002\/cam4.2583 (2019).","journal-title":"Cancer Med."},{"key":"88676_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41416-018-0167-x","volume":"119","author":"NB Wagner","year":"2018","unstructured":"Wagner, N. B., Forschner, A., Leiter, U., Garbe, C. & Eigentler, T. K. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. Br. J. Cancer 119, 339\u2013346. https:\/\/doi.org\/10.1038\/s41416-018-0167-x (2018).","journal-title":"Br. J. Cancer"},{"key":"88676_CR6","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3389\/fonc.2019.01517","volume":"9","author":"Z Wang","year":"2019","unstructured":"Wang, Z., Wang, Y., Peng, M. & Yi, L. UBASH3B is a novel prognostic biomarker and correlated with immune infiltrates in prostate cancer. Front. Oncol. 9, 1517. https:\/\/doi.org\/10.3389\/fonc.2019.01517 (2019).","journal-title":"Front. Oncol."},{"key":"88676_CR7","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1242\/jcs.194886","volume":"129","author":"VA Barr","year":"2016","unstructured":"Barr, V. A. et al. Development of nanoscale structure in LAT-based signaling complexes. J. Cell Sci. 129, 4548\u20134562. https:\/\/doi.org\/10.1242\/jcs.194886 (2016).","journal-title":"J. Cell Sci."},{"key":"88676_CR8","doi-asserted-by":"publisher","first-page":"e0170396","DOI":"10.1371\/journal.pone.0170396","volume":"12","author":"VH Navas","year":"2017","unstructured":"Navas, V. H., Cuche, C., Alcover, A. & Di Bartolo, V. Serine phosphorylation of SLP76 is dispensable for T cell development but modulates helper T cell function. PLoS ONE 12, e0170396. https:\/\/doi.org\/10.1371\/journal.pone.0170396 (2017).","journal-title":"PLoS ONE"},{"key":"88676_CR9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/s1074-7613(01)00244-8","volume":"15","author":"F Michel","year":"2001","unstructured":"Michel, F., Attal-Bonnefoy, G., Mangino, G., Mise-Omata, S. & Acuto, O. CD28 as a molecular amplifier extending TCR ligation and signaling capabilities. Immunity 15, 935\u2013945. https:\/\/doi.org\/10.1016\/s1074-7613(01)00244-8 (2001).","journal-title":"Immunity"},{"key":"88676_CR10","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1002\/eji.201445352","volume":"45","author":"K Lampe","year":"2015","unstructured":"Lampe, K. et al. Slp-76 is a critical determinant of NK-cell mediated recognition of missing-self targets. Eur. J. Immunol. 45, 2072\u20132083. https:\/\/doi.org\/10.1002\/eji.201445352 (2015).","journal-title":"Eur. J. Immunol."},{"key":"88676_CR11","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1074\/mcp.M112.025908","volume":"12","author":"Y Bounab","year":"2013","unstructured":"Bounab, Y. et al. Proteomic analysis of the SH2 domain-containing leukocyte protein of 76 kDa (SLP76) interactome in resting and activated primary mast cells [corrected]. Mol. Cell Proteomics 12, 2874\u20132889. https:\/\/doi.org\/10.1074\/mcp.M112.025908 (2013).","journal-title":"Mol. Cell Proteomics"},{"key":"88676_CR12","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.4049\/jimmunol.1400326","volume":"194","author":"OM Siggs","year":"2015","unstructured":"Siggs, O. M. et al. Quantitative reduction of the TCR adapter protein SLP-76 unbalances immunity and immune regulation. J. Immunol. 194, 2587\u20132595. https:\/\/doi.org\/10.4049\/jimmunol.1400326 (2015).","journal-title":"J. Immunol."},{"key":"88676_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1755-8794-1-13","volume":"1","author":"AI Riker","year":"2008","unstructured":"Riker, A. I. et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med. Genomics 1, 13. https:\/\/doi.org\/10.1186\/1755-8794-1-13 (2008).","journal-title":"BMC Med. Genomics"},{"key":"88676_CR14","doi-asserted-by":"publisher","first-page":"7234","DOI":"10.1158\/1078-0432.CCR-05-0683","volume":"11","author":"D Talantov","year":"2005","unstructured":"Talantov, D. et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 11, 7234\u20137242. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0683 (2005).","journal-title":"Clin. Cancer Res."},{"key":"88676_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565. https:\/\/doi.org\/10.1038\/s41586-019-1914-8 (2020).","journal-title":"Nature"},{"key":"88676_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/ijc.29047","volume":"136","author":"K Jayawardana","year":"2015","unstructured":"Jayawardana, K. et al. Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. Int. J. Cancer 136, 863\u2013874. https:\/\/doi.org\/10.1002\/ijc.29047 (2015).","journal-title":"Int. J. Cancer"},{"key":"88676_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy. Cancer Cell 35, 238-255.e236. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.003 (2019).","journal-title":"Cancer Cell"},{"key":"88676_CR18","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3324\/haematol.2015.139154","volume":"101","author":"N Dezorella","year":"2016","unstructured":"Dezorella, N. et al. SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course. Haematologica 101, 1553\u20131562. https:\/\/doi.org\/10.3324\/haematol.2015.139154 (2016).","journal-title":"Haematologica"},{"key":"88676_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12957-017-1181-9","volume":"15","author":"S Chu","year":"2017","unstructured":"Chu, S., Wang, H. & Yu, M. A putative molecular network associated with colon cancer metastasis constructed from microarray data. World J. Surg. Oncol. 15, 115. https:\/\/doi.org\/10.1186\/s12957-017-1181-9 (2017).","journal-title":"World J. Surg. Oncol."},{"key":"88676_CR20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3892\/ijmm.2018.3631","volume":"42","author":"H Jiang","year":"2018","unstructured":"Jiang, H. et al. Inflammatory genes are novel prognostic biomarkers for colorectal cancer. Int. J. Mol. Med. 42, 368\u2013380. https:\/\/doi.org\/10.3892\/ijmm.2018.3631 (2018).","journal-title":"Int. J. Mol. Med."},{"key":"88676_CR21","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2009-08-237438","volume":"115","author":"GF Sonnenberg","year":"2010","unstructured":"Sonnenberg, G. F. et al. Mislocalization of SLP-76 leads to aberrant inflammatory cytokine and autoantibody production. Blood 115, 2186\u20132195. https:\/\/doi.org\/10.1182\/blood-2009-08-237438 (2010).","journal-title":"Blood"},{"key":"88676_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41590-018-0131-1","volume":"19","author":"WL Lo","year":"2018","unstructured":"Lo, W. L. et al. Lck promotes Zap70-dependent LAT phosphorylation by bridging Zap70 to LAT. Nat. Immunol. 19, 733\u2013741. https:\/\/doi.org\/10.1038\/s41590-018-0131-1 (2018).","journal-title":"Nat. Immunol."},{"key":"88676_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.urolonc.2017.04.007","volume":"36","author":"A Sankin","year":"2018","unstructured":"Sankin, A. et al. The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: what lies beneath the tip of the iceberg, PD-L1. Urol. Oncol. 36, 459\u2013468. https:\/\/doi.org\/10.1016\/j.urolonc.2017.04.007 (2018).","journal-title":"Urol. Oncol."},{"key":"88676_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-019-0819-1","volume":"12","author":"D Liu","year":"2019","unstructured":"Liu, D. CAR-T \u201cthe living drugs\u201d, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J. Hematol. Oncol. 12, 113. https:\/\/doi.org\/10.1186\/s13045-019-0819-1 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"88676_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/CMR.0000000000000515","volume":"29","author":"N Dabrosin","year":"2019","unstructured":"Dabrosin, N. et al. Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status. Melanoma Res. 29, 30\u201337. https:\/\/doi.org\/10.1097\/CMR.0000000000000515 (2019).","journal-title":"Melanoma Res."},{"key":"88676_CR26","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.15252\/embj.201490147","volume":"34","author":"N Antonio","year":"2015","unstructured":"Antonio, N. et al. The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer. EMBO J. 34, 2219\u20132236. https:\/\/doi.org\/10.15252\/embj.201490147 (2015).","journal-title":"EMBO J."},{"key":"88676_CR27","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-17-2257","volume":"24","author":"J Edwards","year":"2018","unstructured":"Edwards, J. et al. CD103(+) Tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment. Clin. Cancer Res. 24, 3036\u20133045. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2257 (2018).","journal-title":"Clin. Cancer Res."},{"key":"88676_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar, D. S. et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19, 649\u2013658. https:\/\/doi.org\/10.1016\/j.neo.2017.05.002 (2017).","journal-title":"Neoplasia"},{"key":"88676_CR29","doi-asserted-by":"publisher","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","volume":"46","author":"SV Vasaikar","year":"2018","unstructured":"Vasaikar, S. V., Straub, P., Wang, J. & Zhang, B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 46, D956\u2013D963. https:\/\/doi.org\/10.1093\/nar\/gkx1090 (2018).","journal-title":"Nucleic Acids Res."},{"key":"88676_CR30","doi-asserted-by":"publisher","first-page":"D545","DOI":"10.1093\/nar\/gkaa970","volume":"49","author":"M Kanehisa","year":"2021","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M. & Tanabe, M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 49, D545\u2013D551. https:\/\/doi.org\/10.1093\/nar\/gkaa970 (2021).","journal-title":"Nucleic Acids Res."},{"key":"88676_CR31","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li, T. et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Can. Res. 77, e108\u2013e110. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0307 (2017).","journal-title":"Can. Res."},{"key":"88676_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457. https:\/\/doi.org\/10.1038\/nmeth.3337 (2015).","journal-title":"Nat. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88676-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88676-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88676-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:23:58Z","timestamp":1670052238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88676-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88676"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88676-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9164"}}